diffusion pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. the company is developing its lead drug, trans sodium crocetinate (tsc), which has received orphan drug designation from the fda for use in a number of cancers in which tumor hypoxia (oxygen deprivation) diminishes the efficacy of current treatments. tsc targets the cancer’s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancerous cells more vulnerable to the therapeutic effects of conventional radiation and chemotherapy. the company is poised to begin a pivotal phase 3 trial in glioblastoma (gbm) in 2016. other programs include planned phase 2/3 trials in pancreatic cancer and brain metastases. because tsc’s novel mechanism safely re-oxygenates a wide range of tumor types, its use is not limited to a specific tumor tissue, but
Company profile
Ticker
CRVO
Exchange
Website
CEO
Robert J. Cobuzzi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Diffusion Pharmaceuticals Inc., FERIS INTERNATIONAL, INC., RestorGenex Corp, Stratus Media Group, Inc, TITAN MOTORCYCLE CO OF AMERICA INC
SEC CIK
Corporate docs
Subsidiaries
EIP Pharma, Inc. • Diffusion Pharmaceuticals LLC ...
IRS number
300645032
CRVO stock data
Latest filings (excl ownership)
8-K
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
5 Apr 24
8-K
Regulation FD Disclosure
4 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
28 Mar 24
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
18 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
8-K
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
7 Feb 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
8-K
CervoMed to Participate in the Emerging Growth Conference 66
5 Jan 24
Latest ownership filings
SC 13G
RA CAPITAL MANAGEMENT, L.P.
11 Apr 24
SC 13G/A
AI EIPP Holdings LLC
6 Mar 24
SC 13D/A
BOGER JOSHUA S
28 Feb 24
4
JOSHUA S BOGER
28 Feb 24
SC 13G/A
AI EIPP Holdings LLC
14 Feb 24
4
JOSHUA S BOGER
13 Feb 24
SC 13D
BOGER JOSHUA S
9 Feb 24
3
JOSHUA S BOGER
9 Feb 24
4
JOHN J ALAM
26 Jan 24
4
Kelly Blackburn
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.42 mm | 10.42 mm | 10.42 mm | 10.42 mm | 10.42 mm | 10.42 mm |
Cash burn (monthly) | 1.52 mm | (no burn) | 891.71 k | 1.11 mm | (no burn) | 1.50 mm |
Cash used (since last report) | 10.16 mm | n/a | 5.94 mm | 7.37 mm | n/a | 9.99 mm |
Cash remaining | 265.99 k | n/a | 4.48 mm | 3.06 mm | n/a | 432.10 k |
Runway (months of cash) | 0.2 | n/a | 5.0 | 2.8 | n/a | 0.3 |
Institutional ownership, Q2 2023
2.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 0 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 455.06 mm |
Total shares | 176.72 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 66.23 k | $221.22 mm |
Renaissance Technologies | 40.31 k | $135.00 k |
BLK Blackrock | 32.85 k | $109.73 mm |
Geode Capital Management | 17.12 k | $56.85 mm |
Bridgeway Capital Management | 16.57 k | $55.00 mm |
Tower Research Capital | 2.41 k | $8.05 mm |
Advisor | 594.00 | $1.98 mm |
MS Morgan Stanley | 548.00 | $1.83 mm |
UBS UBS Group AG - Registered Shares | 60.00 | $200.00 k |
WFC Wells Fargo & Co. | 15.00 | $50.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 24 | Joshua S Boger | Common Stock | Sell | Dispose S | Yes | No | 0 | 36 | 0.00 | 840,451 |
26 Feb 24 | Joshua S Boger | Common Stock | Acquire X | Yes | No | 0 | 495,995 | 0.00 | 840,487 | |
26 Feb 24 | Joshua S Boger | Pre-Funded Common Stock Purchase Warrant Common Stock | Dispose X | Yes | No | 0.001 | 495,995 | 496.00 | 0 | |
12 Feb 24 | Joshua S Boger | Stock Option Common Stock | Grant | Acquire A | No | No | 13.97 | 10,000 | 139.70 k | 10,000 |
26 Jan 24 | John William Tanner | Stock Option Common Stock | Grant | Acquire A | No | No | 9.05 | 16,000 | 144.80 k | 16,000 |
26 Jan 24 | William Robert Elder | Stock Option Common Stock | Grant | Acquire A | No | No | 9.05 | 16,000 | 144.80 k | 16,000 |
News
CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24
15 Apr 24
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
8 Apr 24
Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
8 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Mar 24
CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
5 Mar 24
Press releases
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
2 Apr 24
CervoMed to Participate in the BIO CEO and Investor Conference
21 Feb 24
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
20 Feb 24
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
12 Feb 24
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
7 Feb 24